JNJ 54861911

Drug Profile

JNJ 54861911

Alternative Names: JNJ-54861911

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator Shionogi
  • Developer Janssen Research & Development; Shionogi
  • Class Antidementias; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO, Tablet)
  • 01 Jun 2016 Janssen Research & Development completes a phase I pharmacokinetic interaction trial in Healthy volunteers in Germany (PO) (NCT02611518)
  • 01 Jun 2016 Janssen Research and Development completes a phase IIa trial in Alzheimer's disease (In adults, In elderly) in Belgium, France, Germany, Netherlands, Spain and Sweden (NCT02260674)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top